Fungal Infections During and After the SARS-CoV-2 Pandemic: A Retrospective Comparison

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

1441 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-01

Study Completion Date

2024-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

his study aims to retrospectively compare fungal positivity rates between the SARS-CoV-2 pandemic and the post-pandemic periods. During the pandemic, Candida species had a positivity rate of 17.36%, and Aspergillus had a rate of 2.22%. Post-pandemic, these rates decreased to 9.29% and 1.00%, respectively. The overall fungal positivity rate decreased from 9.15% during the pandemic to 5.13% post-pandemic. Statistical analysis revealed a significant decrease in fungal positivity rates post-pandemic (p \< 0.01). These findings underscore the effectiveness of post-pandemic healthcare interventions and infection control strategies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analysis of Candida-Associated Osteoarticular Infections: Multicenter Turkish Data

NCT06788782

Candida Osteomyelitis Candida Infection Arthritis +1 more

COMPLETED

Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp

NCT02646800

Aspergillosis Candidiasis

TERMINATED PHASE4

Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia

NCT00106288

Candidiasis

COMPLETED PHASE3

Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)

NCT00083343

Candidiasis

COMPLETED PHASE2

Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia

NCT00189709

Invasive Candidiasis Candidemia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study aims to retrospectively compare fungal positivity rates by focusing on Candida and Aspergillus species during the SARS-CoV-2 pandemic and in the post-pandemic period. The dataset includes samples collected during the pandemic period (N=623) and the subsequent post-pandemic period (N=818). Fungal positivity rates were calculated and statistically analyzed using chi-square tests, and significance was determined as p\<0.01.

During the SARS-CoV-2 pandemic, Candida species showed a positivity rate of 17.36%, while the rate in the post-pandemic period significantly decreased to 9.29% (p=0.002). In contrast, Aspergillus species did not show a significant change in positivity rates between the pandemic (2.22%) and post-pandemic (1.00%) periods (p=0.186, NS).

Overall, the study provides valuable insights into the epidemiology of fungal infections during and after the SARS-CoV-2 pandemic, suggesting possible shifts in fungal pathogen prevalence and healthcare priorities. The findings contribute to the development of targeted healthcare strategies and surveillance measures for fungal infections in the post-pandemic era.

Study Design: Retrospective comparative analysis

Data Analysis: Chi-square tests, p\<0.01 considered significant

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fungal Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The percentages of fungus positivity in the SARS CoV-2 pandemic and SARS CoV-2 post-pandemic period

The study was conducted retrospectively, analyzing a total of 1441 patients. Among these, 623 were during the SARS-CoV-2 pandemic and 818 were in the post-pandemic period. Fungal positivity rates were calculated separately for different fungal agents including Candida species and Aspergillus. These rates were presented as percentages and statistically compared between the two periods.

Culture, İsolation

Intervention Type DIAGNOSTIC_TEST

Data on patient demographics, clinical conditions, and fungal infection positivity rates were extracted from hospital records. Fungal positivity rates were calculated based on laboratory results and presented as percentages. Statistical analyses were performed using the Chi-Square test, and p-values were reported.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Culture, İsolation

Data on patient demographics, clinical conditions, and fungal infection positivity rates were extracted from hospital records. Fungal positivity rates were calculated based on laboratory results and presented as percentages. Statistical analyses were performed using the Chi-Square test, and p-values were reported.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients over 18 years of age of both genders

Exclusion Criteria

* Patients under 18 years of age,
* Patients whose demographic, clinical and laboratory data investigated in the study could not be accessed, patients who were diagnosed with fungal infection during hospitalization

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes